v3.3.1.900
Segments of Business and Geographic Areas
 12 Months Ended
Jan. 03, 2016
Segment Reporting [Abstract]  
SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS
Segments of Business and Geographic Areas
 
 
Sales to Customers
(Dollars in Millions)
 
2015
 
2014
 
2013
Consumer —
 
 
 
 
 
 
United States
 
$
5,222

 
5,096

 
5,162

International
 
8,285

 
9,400

 
9,535

Total
 
13,507

 
14,496

 
14,697

Pharmaceutical —
 
 
 
 
 
 
United States
 
18,333

 
17,432

 
13,948

International
 
13,097

 
14,881

 
14,177

Total
 
31,430

 
32,313

 
28,125

Medical Devices —
 
 
 
 
 
 
United States
 
12,132

 
12,254

 
12,800

International
 
13,005

 
15,268

 
15,690

Total
 
25,137

 
27,522

 
28,490

Worldwide total
 
$
70,074

 
74,331

 
71,312


 
 
Income Before Tax
 
Identifiable Assets
(Dollars in Millions)
 
2015 (3)
 
2014 (4)
 
2013 (5)
 
2015
 
2014
Consumer
 
$
1,787

 
1,941

 
1,973

 
20,772

 
21,813

Pharmaceutical
 
11,734

 
11,696

 
9,178

 
26,144

 
25,803

Medical Devices
 
6,826

 
7,953

 
5,261

 
40,979

 
41,445

Total
 
20,347

 
21,590

 
16,412

 
87,895

 
89,061

Less: Expense not allocated to segments (1)
 
1,151

 
1,027

 
941

 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
45,516

 
41,297

Worldwide total
 
$
19,196

 
20,563

 
15,471

 
$
133,411

 
130,358


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2015
 
2014
 
2013
 
2015
 
2014
 
2013
Consumer
 
$
544

 
581

 
533

 
$
559

 
577

 
539

Pharmaceutical
 
1,063

 
977

 
856

 
929

 
1,053

 
1,075

Medical Devices
 
1,631

 
1,807

 
1,724

 
1,945

 
1,974

 
2,224

Segments total
 
3,238

 
3,365

 
3,113

 
3,433

 
3,604

 
3,838

General corporate
 
225

 
349

 
482

 
313

 
291

 
266

Worldwide total
 
$
3,463

 
3,714

 
3,595

 
$
3,746

 
3,895

 
4,104


 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2015
 
2014
 
2013
 
2015
 
2014
United States
 
$
35,687

 
34,782

 
31,910

 
36,609

 
36,835

Europe
 
15,995

 
18,947

 
18,599

 
20,167

 
21,559

Western Hemisphere excluding U.S. 
 
6,045

 
7,160

 
7,421

 
2,881

 
3,210

Asia-Pacific, Africa
 
12,347

 
13,442

 
13,382

 
2,493

 
2,438

Segments total
 
70,074

 
74,331

 
71,312

 
62,150

 
64,042

General corporate
 
 
 
 
 
 
 
1,148

 
1,138

Other non long-lived assets
 
 
 
 
 
 
 
70,113

 
65,178

Worldwide total
 
$
70,074

 
74,331

 
71,312

 
133,411

 
130,358

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2015 and 2014, the Company had one wholesaler distributing products for all three segments that represented approximately 12.5% and 11.0%, respectively, of the total consolidated revenues. In 2013, the Company did not have a customer that represented 10.0% of total revenues.
(1) 
Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense.
(2) 
General corporate includes cash, cash equivalents and marketable securities.
(3) 
The Medical Devices segment includes a restructuring charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA® and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA® brand.
(4) 
Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. The Pharmaceutical segment includes an additional year of the Branded Prescription Drug Fee of $220 million and a positive adjustment of $0.1 billion to previous reserve estimates.
(5) 
Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
(6) 
Long-lived assets include property, plant and equipment, net for 2015, and 2014 of $15,905 and $16,126, respectively, and intangible assets and goodwill, net for 2015 and 2014 of $47,393 and $49,054, respectively.